Bio-Gene Technology Limited EBIT

As of the most recent data (June 2026), BGT.AX shows a EBIT of $-5.5M. That compares with $-6M in the prior-year period — up 9.3% year over year. That is below the sector sector average of $2.6T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BGT.AX's EBIT is now $-5.5M (was $-6M) — a 9.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bio-Gene Technology Limited is outperforming or lagging.

The its sector sector average EBIT is about $2.6T. Bio-Gene Technology Limited is at $-5.5M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how BGT.AX stacks up against individual peers as well.

Tracking BGT.AX's ebit over time shows whether Bio-Gene Technology Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $-5.5M That compares with $-6M in the prior-year period — up 9.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Bio-Gene Technology Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-5.5M) with ownership activity and broader fundamentals.